About this article Cite this article Lyons, H.E., Peel, A., Gonzalez, M
For patients classified as obese, with a body mass index (BMI) of 30 or higher, or those who are overweight with a BMI of 27 or higher and have additional weight-related health conditions, Ozempic may be considered as part of a comprehensive treatment plan
In addition to managing blood sugar, Semanat 4mg/3ml Multiple Dose Vial Injection 10ml provides broader metabolic benefits, such as improvements in cardiometabolic risk factors
In comparison, the 2.4 mg Wegovy injection can support an average weight loss of 17.5%, while the maximum 7.2 mg has achieved an average weight loss of 20.7% over 72 weeks in the STEP UP trial
Branded Alternatives: A Clinical Comparison GLP-1 receptor agonistssemaglutide, tirzepatide, and emerging compounds like retatrutideare available through branded pharmaceutical channels (Ozempic, Wegovy, Mounjaro, Zepbound) and licensed 503A compounding pharmacies